+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Blood Cancer Drugs Market - Global Forecast 2026-2032- Product Image
New

Blood Cancer Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010967
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The blood cancer drugs market is evolving rapidly as scientific innovation, new care models, and rising patient expectations drive fundamental changes across development, delivery, and access for hematologic oncology treatments. Senior decision-makers must understand how these converging trends shape therapeutic adoption and strategic prioritization in a highly complex landscape.

Market Snapshot: Blood Cancer Drugs Market Overview

The Blood Cancer Drugs Market grew from USD 50.96 billion in 2025 to USD 56.49 billion in 2026. It is expected to continue expanding at a CAGR of 12.04%, reaching USD 112.95 billion by 2032. This growth is underpinned by advances in targeted therapies, immunotherapies, and cell-based approaches, while operational challenges and shifting care delivery models influence both adoption and outcomes.

Scope & Segmentation

  • Therapeutic Classes: Includes cytotoxic agents, immunotherapies, targeted therapies, and stem cell transplant procedures, each requiring specific care pathways and infrastructure investments.
  • Clinical Indications: Covers acute and chronic leukemias, lymphoma (Hodgkin and non-Hodgkin), multiple myeloma, and myelodysplastic syndromes, reflecting broad clinical heterogeneity and diverse biomarker landscapes.
  • Administration Routes: Examines intravenous, oral, and subcutaneous treatments—each impacting patient experience, clinical workflow, and infrastructure use.
  • Distribution Channels: Hospital pharmacies, retail and online pharmacies facilitate hospital-based, outpatient, and home-based therapy delivery.
  • End-User Settings: Hospitals, clinics, and home care providers shape procurement processes, clinical competencies, and adoption trajectories.
  • Regional Coverage: Americas, Europe, Middle East & Africa, Asia-Pacific—each region brings distinct regulatory, infrastructure, payer, and clinical dynamics that inform access and commercialization strategies.
  • Technology & Innovation: Focuses on biomarker-guided development, digital health, remote monitoring, and advanced manufacturing practices enabling targeted and decentralized therapy deployment.

Key Takeaways for Decision-Makers

  • The shift toward precision medicine and value-based arrangements is altering payer-provider dynamics and driving adoption of molecularly targeted therapies in hematologic oncology.
  • Operational readiness—including expansion of outpatient and home-based delivery models—directly impacts the reach and real-world feasibility of advanced blood cancer treatments.
  • Collaboration between developers, manufacturers, and distribution partners supports scaling of complex modalities such as cell therapies and biologics.
  • Segment-specific factors, such as clinical indication and administration route, are critical for product development, launch sequencing, and optimal market penetration.
  • Regional nuances in regulation, infrastructure, and payer engagement require tailored market entry and commercialization strategies rather than uniform global approaches.

Tariff Impact on Supply Chain and Competitive Decisions

Tariff policies and trade measures influence therapeutic supply chain agility, especially for biologics and advanced therapies dependent on globalized logistics. Changes in import duties, customs procedures, or regulatory alignment can affect manufacturing decisions, inventory management, and overall access to innovative treatments. Companies must proactively assess tariff scenarios to adjust sourcing strategies and minimize disruptions to sensitive product flows.

Methodology & Data Sources

Research integrates primary interviews with clinicians, supply chain leaders, payers, and industry executives, alongside secondary sources such as peer-reviewed literature, regulatory guidance, clinical trials data, and corporate filings. Analytical tools include qualitative synthesizing, structured comparison, and scenario analysis to validate findings and inform actionable conclusions.

Why This Blood Cancer Drugs Market Report Matters

  • Provides an integrated perspective that links clinical innovation, operational realities, and regional trends for robust market assessment and risk mitigation.
  • Enables senior leaders to align R&D, manufacturing, and commercial tactics with emerging care models and evolving payer requirements.
  • Supports strategic planning by highlighting actionable segmentation insights and evidence-driven recommendations for differentiated positioning.

Conclusion

Real-world adoption of blood cancer drugs depends on effective integration of clinical, operational, and regional strategies. Ongoing evidence generation and collaboration are vital for sustained success in this dynamic therapeutic arena.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Blood Cancer Drugs Market, by Therapeutic Class
8.1. Chemotherapy
8.2. Immunotherapy
8.3. Stem Cell Transplant
8.4. Targeted Therapy
9. Blood Cancer Drugs Market, by Indication
9.1. Leukemia
9.1.1. Acute Lymphoblastic Leukemia
9.1.2. Acute Myeloid Leukemia
9.1.3. Chronic Lymphocytic Leukemia
9.1.4. Chronic Myeloid Leukemia
9.2. Lymphoma
9.2.1. Hodgkin Lymphoma
9.2.2. Non-Hodgkin Lymphoma
9.3. Multiple Myeloma
9.3.1. First Line
9.3.2. Second Line
9.3.3. Third Line And Later
9.4. Myelodysplastic Syndromes
10. Blood Cancer Drugs Market, by Route Of Administration
10.1. Intravenous
10.2. Oral
10.3. Subcutaneous
11. Blood Cancer Drugs Market, by End User
11.1. Clinics
11.2. Home Care
11.3. Hospitals
12. Blood Cancer Drugs Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Blood Cancer Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Blood Cancer Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Blood Cancer Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Blood Cancer Drugs Market
17. China Blood Cancer Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc
18.6. Amgen Inc
18.7. Astellas Pharma Inc
18.8. AstraZeneca plc
18.9. Bayer AG
18.10. BeiGene Ltd
18.11. Bristol-Myers Squibb Company
18.12. Celgene Corporation
18.13. Cipla Limited
18.14. Dr. Reddy’s Laboratories Ltd
18.15. Eli Lilly and Company
18.16. Gilead Sciences Inc
18.17. GlaxoSmithKline plc
18.18. Incyte Corporation
18.19. Johnson & Johnson
18.20. Merck & Co., Inc.
18.21. Novartis AG
18.22. Ono Pharmaceutical Co., Ltd
18.23. Pfizer Inc
18.24. Roche Holding AG
18.25. Sanofi S.A.
18.26. Sun Pharmaceutical Industries Limited
18.27. Takeda Pharmaceutical Company Limited
18.28. Teva Pharmaceutical Industries Ltd
18.29. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 127. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 129. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 130. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 131. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 145. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 147. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 148. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 149. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 164. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 166. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 167. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 168. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. GCC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. GCC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 173. GCC BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 174. GCC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 175. GCC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 176. GCC BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 177. GCC BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. GCC BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. GCC BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 191. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 192. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 193. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 194. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 195. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. G7 BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. G7 BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 200. G7 BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 201. G7 BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 202. G7 BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 203. G7 BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 204. G7 BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. G7 BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. G7 BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. NATO BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. NATO BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 209. NATO BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 210. NATO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 211. NATO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 212. NATO BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 213. NATO BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. NATO BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. NATO BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. CHINA BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 227. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 228. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 229. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 230. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 231. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2032 (USD MILLION)
TABLE 232. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Blood Cancer Drugs market report include:
  • AbbVie Inc
  • Amgen Inc
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • BeiGene Ltd
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd
  • Eli Lilly and Company
  • Gilead Sciences Inc
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 56.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 112.95 Billion
Compound Annual Growth Rate12.0%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Blood Cancer Drugs Market Report 2025 - Product Image

Blood Cancer Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Blood Cancer Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Blood Cancer Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Oncology Drugs Market - Global Forecast 2026-2032 - Product Image

Oncology Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Hematologic Malignancies Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Hematologic Malignancies Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Antitumor ADC Drugs Market - Global Forecast 2026-2032 - Product Image

Antitumor ADC Drugs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From

About the Blood Cancer Drug Market

The Blood Cancer Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Blood cancer drugs are used to treat a variety of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are typically administered intravenously or orally, and may include chemotherapy, targeted therapy, and immunotherapy. Blood cancer drugs are designed to target cancer cells while minimizing damage to healthy cells, and may be used in combination with other treatments. The Blood Cancer Drug market is highly competitive, with a number of large pharmaceutical companies offering a range of treatments. Companies in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Merck. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.